GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Immunovant
IMVT
$2.99B
| $76.3K | ﹤0.01% |
+3,082
| New | +$76.3K |
|
352
CareTrust REIT
CTRE
$7.56B
| $75.8K | ﹤0.01% |
+2,802
| New | +$75.8K |
|
353
Berkshire Hathaway Class B
BRK.B
$1.08T
| $74.8K | ﹤0.01% |
+165
| New | +$74.8K |
|
354
Alvotech
ALVO
$2.6B
| $74.1K | ﹤0.01% |
+5,603
| New | +$74.1K |
|
355
Sabra Healthcare REIT
SBRA
$4.56B
| $73.7K | ﹤0.01% |
+4,257
| New | +$73.7K |
|
356
PTC Therapeutics
PTCT
$4.55B
| $73.1K | ﹤0.01% |
+1,619
| New | +$73.1K |
|
357
Avidity Biosciences
RNA
$6.48B
| $72.8K | ﹤0.01% |
+2,505
| New | +$72.8K |
|
358
Rhythm Pharmaceuticals
RYTM
$6.78B
| $72.2K | ﹤0.01% |
+1,290
| New | +$72.2K |
|
|
VRNA
359
Verona Pharma
VRNA
$9.2B
| $72.1K | ﹤0.01% |
+1,553
| New | +$72.1K |
|
360
CRISPR Therapeutics
CRSP
$4.99B
| $70.5K | ﹤0.01% |
+1,792
| New | +$70.5K |
|
361
Tanger
SKT
$3.94B
| $67.8K | ﹤0.01% |
+1,987
| New | +$67.8K |
|
362
NovoCure
NVCR
$1.37B
| $67.7K | ﹤0.01% |
+2,272
| New | +$67.7K |
|
363
Citigroup
C
$176B
| $65.6K | ﹤0.01% |
+932
| New | +$65.6K |
|
364
Veracyte
VCYT
$2.55B
| $64.4K | ﹤0.01% |
+1,627
| New | +$64.4K |
|
365
Acadia Pharmaceuticals
ACAD
$4.26B
| $64.1K | ﹤0.01% |
+3,494
| New | +$64.1K |
|
366
Apple Hospitality REIT
APLE
$3.09B
| $63.8K | ﹤0.01% |
+4,156
| New | +$63.8K |
|
367
COPT Defense Properties
CDP
$3.46B
| $63.4K | ﹤0.01% |
+2,047
| New | +$63.4K |
|
368
Xenon Pharmaceuticals
XENE
$3.02B
| $62.8K | ﹤0.01% |
+1,601
| New | +$62.8K |
|
369
Denali Therapeutics
DNLI
$2.26B
| $61.6K | ﹤0.01% |
+3,022
| New | +$61.6K |
|
370
EPR Properties
EPR
$4.05B
| $60.9K | ﹤0.01% |
+1,376
| New | +$60.9K |
|
371
Merus
MRUS
$5.1B
| $60.5K | ﹤0.01% |
+1,438
| New | +$60.5K |
|
372
Amicus Therapeutics
FOLD
$2.46B
| $59.1K | ﹤0.01% |
+6,274
| New | +$59.1K |
|
373
Janux Therapeutics
JANX
$1.44B
| $59K | ﹤0.01% |
+1,102
| New | +$59K |
|
374
Highwoods Properties
HIW
$3.44B
| $58.9K | ﹤0.01% |
+1,926
| New | +$58.9K |
|
375
National Health Investors
NHI
$3.72B
| $58.2K | ﹤0.01% |
+840
| New | +$58.2K |
|